NVS Jan 2024 80.000 call
| Previous close | 11.00 |
| Open | 8.00 |
| Bid | 13.30 |
| Ask | 15.50 |
| Strike | 80.00 |
| Expiry date | 2024-01-19 |
| Day's range | 8.00 - 11.00 |
| Contract range | N/A |
| Volume | |
| Open interest | 247 |
- Simply Wall St.
Novartis AG's (VTX:NOVN) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?
Novartis (VTX:NOVN) has had a great run on the share market with its stock up by a significant 5.6% over the last...
- Zacks
Novartis (NVS) Set to Advance Malaria Drug Into Phase III
Novartis (NVS) plans to advance ganaplacide/lumefantrine into a phase III study for the treatment of patients with acute uncomplicated malaria due to Plasmodium falciparum.
- GlobeNewswire
Novartis highlights scientific advances with Kisqali, iptacopan, Scemblix and YTB323 data at SABCS and ASH
First data to be presented as a late-breaker abstract from global pivotal APPLY-PNH trial of investigational oral monotherapy iptacopan in paroxysmal nocturnal hemoglobinaria (PNH), a rare and serious complement-mediated blood disorder New data evaluating the superiority of first-line (1L) Kisqali® plus endocrine therapy vs. combination chemotherapy in pre-menopausal patients with HR+/HER2- metastatic breast cancer with aggressive disease, including patients with visceral disease New analysis fr
